List of Tivorbex drug patents
Tivorbex is owned by Genus.
Tivorbex contains Indomethacin.
Tivorbex has a total of 3 drug patents out of which 0 drug patents have expired.
Tivorbex was authorised for market use on 24 February, 2014.
Tivorbex is available in capsule;oral dosage forms.
Tivorbex can be used as treatment of pain.
The generics of Tivorbex are possible to be released after 23 April, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734847 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| US8992982 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
| US9089471 | GENUS | Formulation of indomethacin |
Apr, 2030
(6 years from now) | |
Drugs and Companies using INDOMETHACIN ingredient
Market Authorisation Date: 24 February, 2014
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
TIVORBEX family patents
10
United States
5
Australia
3
Japan
3
New Zealand
3
Korea, Republic of
2
China
2
Singapore
2
Israel
1
Malaysia
1
Denmark
1
AP
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
Mexico
1
South Africa
1
Colombia
1
Tunisia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic